Ameloblastoma - dismech

◆

Subtypes

4

Conventional (solid/multicystic) ameloblastoma

The most common type (previously termed solid/multicystic), usually mandibular, locally aggressive with the highest recurrence risk. Histologic patterns include follicular, plexiform, acanthomatous, granular cell, basal cell, and desmoplastic.

Unicystic

Approximately 5-22% of ameloblastomas; occurs in younger patients and may mimic a dentigerous cyst radiographically. Luminal and intraluminal variants are managed conservatively, whereas the mural variant behaves like conventional ameloblastoma.

Peripheral (extraosseous) ameloblastoma

Rare soft-tissue variant overlying the jaws, generally less aggressive than intraosseous forms.

Metastasizing

Rare; classified as benign despite metastatic potential (most commonly to the lungs) because the metastatic deposits retain benign ameloblastoma histology.

⚙

Pathophysiology

4

BRAF V600E and MAPK-Pathway Activating Mutation

Somatic activating mutations in the MAPK pathway, most commonly BRAF V600E (valine-to-glutamic-acid substitution at codon 600; pooled prevalence ~70% across 833 cases), lock BRAF kinase in a constitutively active state. Additional MAPK drivers include FGFR2 (upstream RTK), KRAS, NRAS, and HRAS. These mutations are most frequent in mandibular tumors.

odontogenic epithelial cell CL:0000059

MAPK cascade GO:0000165 ↑ INCREASED

Downstream

Constitutive Odontogenic Epithelial Proliferation Constitutively active BRAF continuously phosphorylates MEK and ERK, driving growth-promoting transcription independent of upstream growth-factor signaling.

Show evidence (2 references)

PMID:36428683 SUPPORT Human Clinical

"Meta-analysis prevalence of BRAF V600E in ameloblastoma was 70.49%, and a significant meta-analysis association was reported for those younger than 54 years old and in the mandible."

Meta-analysis of 833 cases establishes BRAF V600E as the dominant somatic driver and its enrichment in mandibular tumors.

PMID:35689405 SUPPORT In Vitro

"we report the establishment of 6 new AB cell lines-generated by "conditional reprogramming"-and their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."

Genomic characterization of patient-derived ameloblastoma cell lines confirms the spectrum of MAPK-pathway driver mutations (FGFR2, KRAS, NRAS, BRAF).

Hedgehog Pathway SMO Activating Mutation

Activating mutations in SMO (Smoothened), most commonly SMO-L412F and less commonly SMO-W535L, drive ligand-independent Hedgehog signaling and GLI-driven transcription. SMO mutations are more typical of maxillary ameloblastomas and represent an alternative oncogenic route to odontogenic epithelial proliferation.

odontogenic epithelial cell CL:0000059

smoothened signaling pathway GO:0007224 ↑ INCREASED

Downstream

Constitutive Odontogenic Epithelial Proliferation Constitutive SMO activation drives GLI-dependent transcription of proliferation and differentiation genes in odontogenic epithelium.

Show evidence (1 reference)

PMID:35689405 SUPPORT In Vitro

"AB cells with activating SMO-L412F mutation (Hedgehog pathway) are insensitive to vismodegib; however, a distinct small-molecule SMO inhibitor, BMS-833923, significantly reduces both downstream Hedgehog signaling and tumor cell viability."

Functional data confirm constitutive Hedgehog signaling driven by the SMO-L412F mutation in ameloblastoma cells.

Constitutive Odontogenic Epithelial Proliferation

Convergent MAPK and Hedgehog signaling drive uncontrolled proliferation of odontogenic epithelial cells with evasion of apoptosis, producing the islands, cords, and sheets of tumor epithelium characteristic of ameloblastoma.

odontogenic epithelial cell CL:0000059

epithelial cell proliferation GO:0050679 ↑ INCREASED apoptosis evasion GO:0043066 ↑ INCREASED

Downstream

Local Bone Invasion and Destruction Expanding tumor epithelium infiltrates medullary spaces and resorbs cortical bone of the jaw.

Show evidence (1 reference)

PMID:38812739 SUPPORT Computational

"Ameloblastoma (AM) is a benign tumor locally originated from odontogenic epithelium that is commonly found in the jaw. This tumor makes aggressive invasions and has a high recurrence rate."

Transcriptomic and network analysis characterizes ameloblastoma as an odontogenic-epithelium-derived tumor with aggressive, invasive proliferation.

Local Bone Invasion and Destruction

The locally invasive tumor infiltrates through the medullary spaces of the jawbone and resorbs cortical bone, destroying normal bone architecture and creating the characteristic unilocular or multilocular radiolucencies. Infiltration beyond radiographic margins underlies the high recurrence rate.

osteoclast CL:0000092

bone resorption GO:0045453 ↑ INCREASED

Downstream

Jaw Swelling Progressive tumor growth and cortical expansion produce painless jaw swelling.

Tooth Malposition Tumor expansion displaces teeth within the affected jaw region.

Facial Asymmetry Unilateral jaw expansion produces visible facial deformity.

Paresthesia Tumor involvement of the inferior alveolar nerve produces altered sensation.

Show evidence (1 reference)

PMID:35689405 SUPPORT Human Clinical

"Although relatively uncommon and rarely metastatic, AB tumors are locally invasive and destructive to the jawbone and surrounding structures."

Describes the locally invasive, bone-destructive behavior that produces the clinical phenotypes of ameloblastoma.

✶

Histopathology

2

Follicular Pattern FREQUENT

Islands of odontogenic epithelium with peripheral palisading and reverse polarization surrounding a central stellate reticulum-like tissue; the most common histologic pattern globally.

Show evidence (1 reference)

PMID:30614154 SUPPORT Human Clinical

"The histopathologic patterns were mostly follicular and plexiform."

Systematic review of 6,446 patients identifies follicular as a predominant histopathologic pattern.

Plexiform Pattern FREQUENT

Anastomosing cords and sheets of odontogenic epithelium; the second most common histologic pattern.

Show evidence (1 reference)

PMID:30614154 SUPPORT Human Clinical

"The histopathologic patterns were mostly follicular and plexiform."

Systematic review identifies plexiform as a predominant histopathologic pattern.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

6

Head and Neck 1

Facial Asymmetry Facial asymmetry HP:0000324

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:38021761 PARTIAL Human Clinical

"This neoplasia is distinguished by exhibiting several clinical and histological variants along with several mutations that affect its behavior."

Indirect support: facial asymmetry arises from progressive unilateral jaw expansion in advanced ameloblastoma. The abstract speaks to clinical variability but does not name facial asymmetry directly, so the link is marked PARTIAL.

Nervous System 1

Paresthesia Paresthesia HP:0003401

Show evidence (1 reference)

PMID:35689405 PARTIAL Human Clinical

"AB tumors are locally invasive and destructive to the jawbone and surrounding structures."

Invasion of surrounding structures, including the inferior alveolar nerve canal, produces paresthesia; this snippet supports the local-invasion basis of the phenotype rather than the symptom frequency.

Other 4

Jaw Swelling Jaw swelling HP:0030793

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:38927880 PARTIAL Human Clinical

"Ameloblastoma, a benign yet aggressive odontogenic tumor known for its recurrence and the severe morbidity from radical surgeries, may benefit from advancements in targeted therapy."

Indirect support: the cited quote establishes ameloblastoma as a benign but locally aggressive jaw tumor. Jaw swelling is the well-recognized hallmark presentation clinically, but this abstract does not name the swelling phenotype directly, so the association is marked PARTIAL.

Odontogenic Neoplasm Odontogenic neoplasm HP:0100612

Show evidence (1 reference)

PMID:38021761 SUPPORT Human Clinical

"Ameloblastoma is one of the most prevalent but enigmatic benign odontogenic tumors of the jaw, accounting for approximately 10% of all maxillary and mandibular tumors."

Confirms ameloblastoma as a benign odontogenic tumor of the jaw.

Tooth Malposition Tooth malposition HP:0000692

Show evidence (1 reference)

PMID:30614154 PARTIAL Human Clinical

"A slight male preference (53%) was found, and the mandible appeared to be the preferred site."

Indirect support: mandibular tumors (the preferred site established by this meta-analysis) characteristically displace teeth as they expand, but the abstract does not name tooth displacement directly, so the link is PARTIAL.

Premature Loss of Teeth Premature loss of teeth HP:0006480

Show evidence (1 reference)

PMID:35689405 PARTIAL Human Clinical

"AB tumors are locally invasive and destructive to the jawbone and surrounding structures."

Indirect support: local destruction of the jawbone and surrounding structures plausibly underlies tooth loss, but the abstract does not name tooth loss directly, so the link is marked PARTIAL.

🧬

Genetic Associations

6

BRAF

Gene: BRAF hgnc:1097

Show evidence (1 reference)

PMID:36428683 SUPPORT Human Clinical

"The discovery that ameloblastoma has a high mutation incidence of BRAF V600E may enable a better investigation of pathophysiology."

Establishes BRAF V600E as the high-frequency somatic driver of ameloblastoma.

SMO

Gene: SMO hgnc:11119

Show evidence (1 reference)

PMID:35689405 SUPPORT In Vitro

"AB cells with activating SMO-L412F mutation (Hedgehog pathway) are insensitive to vismodegib; however, a distinct small-molecule SMO inhibitor, BMS-833923, significantly reduces both downstream Hedgehog signaling and tumor cell viability."

Confirms the activating SMO-L412F mutation and its Hedgehog-pathway consequences in ameloblastoma cells.

FGFR2

Gene: FGFR2 hgnc:3689

Show evidence (1 reference)

PMID:35689405 SUPPORT In Vitro

"their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."

Genomic characterization of ameloblastoma cell lines identifies FGFR2 among the driver mutations.

KRAS

Gene: KRAS hgnc:6407

Show evidence (1 reference)

PMID:35689405 SUPPORT In Vitro

"AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."

Confirms KRAS as a MAPK-pathway driver and establishes MEK-inhibitor sensitivity.

NRAS

Gene: NRAS hgnc:7989

Show evidence (1 reference)

PMID:35689405 SUPPORT In Vitro

"AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."

Confirms NRAS as a MAPK-pathway driver in ameloblastoma.

HRAS

Gene: HRAS hgnc:5173

Show evidence (1 reference)

PMID:35689405 PARTIAL In Vitro

"Recent genomic studies of AB have uncovered oncogenic driver mutations, including in the mitogen-activated protein kinase (MAPK) and Hedgehog signaling pathways."

HRAS is part of the RAS family of MAPK-pathway drivers uncovered in genomic studies of ameloblastoma.

💊

Medical Actions

3

Radical Surgical Resection

Action: surgical procedure MAXO:0000004

Segmental mandibulectomy or maxillectomy with 1.5-2 cm safety margins (en bloc resection), typically with immediate reconstruction (e.g., vascularized fibula free flap). Radical resection achieves the lowest recurrence rate (~11%) but carries significant functional and aesthetic morbidity.

Show evidence (1 reference)

PMID:38927880 SUPPORT Human Clinical

"Ameloblastoma, a benign yet aggressive odontogenic tumor known for its recurrence and the severe morbidity from radical surgeries, may benefit from advancements in targeted therapy."

Establishes radical surgery as the standard treatment and the source of severe morbidity that motivates targeted alternatives.

Conservative Surgical Resection

Action: surgical procedure MAXO:0000004

Enucleation, curettage, or marginal resection for smaller lesions, unicystic luminal/intraluminal types, and younger patients. Offers better functional and aesthetic outcomes but carries a substantially higher recurrence rate (up to 65%).

Show evidence (1 reference)

PMID:38021761 SUPPORT Human Clinical

"The ameloblastoma treatment plan is determined by the tumor's size, anatomical location, histologic variant, and anatomical involvement."

Supports the size/location/variant-driven choice between conservative and radical surgical approaches.

BRAF/MEK Inhibitor Targeted Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: dabrafenib CHEBI:75045 trametinib CHEBI:75998 vemurafenib CHEBI:63637

Pharmacotherapy targeting the MAPK pathway in BRAF V600E-mutant ameloblastoma, typically dabrafenib (BRAF inhibitor) combined with trametinib (MEK inhibitor), or vemurafenib. Used as neoadjuvant therapy to shrink tumors before conservative surgery, and in recurrent, metastatic, or unresectable disease. A systematic review of 23 patients reported that nearly all responded, with 4 complete radiologic remissions.

Mechanism Target:

BRAF V600E and MAPK-Pathway Activating Mutation

Show evidence (2 references)

PMID:38927880 SUPPORT Human Clinical

"covering 23 patients treated with MAPK inhibitor therapies. The results were promising as nearly all patients showed a positive treatment response, with four achieving complete radiological remission and others showing substantial reductions in primary, recurrent, and metastatic ameloblastoma sizes."

Systematic review evidence that anti-MAPK targeted therapy produces responses, including complete remissions, in ameloblastoma.

PMID:37115331 SUPPORT Human Clinical

"These included seven case reports with nine patients who underwent monotherapy with Dabrafenib or Vemurafenib or combination therapy with Dabrafenib and Trametinib."

Documents the BRAF/MEK inhibitor regimens (dabrafenib, vemurafenib, dabrafenib plus trametinib) used in BRAF V600E-mutant ameloblastoma.

{ }

Source YAML

click to show

name: Ameloblastoma
creation_date: "2026-06-22T00:00:00Z"
description: >-
  Ameloblastoma is the most common epithelial odontogenic tumor, arising from the
  epithelial component of the developing tooth (rests of dental lamina, the enamel
  organ, the lining of odontogenic cysts, or basal cells of the oral mucosa). It
  usually affects the molar-ramus region of the mandible (~80% of cases) and less
  commonly the maxilla. Although histologically benign, ameloblastoma is locally
  aggressive, slow-growing, and destructive, with a high recurrence rate after
  incomplete resection and rare metastatic potential. The dominant molecular driver
  is somatic activation of the MAPK pathway, most commonly the BRAF V600E mutation
  (pooled prevalence ~70%, enriched in mandibular tumors), with additional MAPK
  drivers (FGFR2, KRAS, NRAS, HRAS) and Hedgehog-pathway SMO mutations (more typical
  of maxillary tumors). These mutations drive constitutive signaling and uncontrolled
  proliferation of odontogenic epithelium. BRAF V600E status defines a precision-
  oncology target, with BRAF/MEK inhibitors (dabrafenib plus trametinib) showing
  promising responses.
categories:
- Odontogenic Tumor
- Oncogene-Driven Cancer
parents:
- odontogenic neoplasm
disease_term:
  preferred_term: ameloblastoma
  term:
    id: MONDO:0017795
    label: ameloblastoma
has_subtypes:
- name: Conventional
  display_name: Conventional (solid/multicystic) ameloblastoma
  description: >-
    The most common type (previously termed solid/multicystic), usually mandibular,
    locally aggressive with the highest recurrence risk. Histologic patterns include
    follicular, plexiform, acanthomatous, granular cell, basal cell, and desmoplastic.
- name: Unicystic
  description: >-
    Approximately 5-22% of ameloblastomas; occurs in younger patients and may mimic
    a dentigerous cyst radiographically. Luminal and intraluminal variants are managed
    conservatively, whereas the mural variant behaves like conventional ameloblastoma.
- name: Peripheral
  display_name: Peripheral (extraosseous) ameloblastoma
  description: >-
    Rare soft-tissue variant overlying the jaws, generally less aggressive than
    intraosseous forms.
- name: Metastasizing
  description: >-
    Rare; classified as benign despite metastatic potential (most commonly to the
    lungs) because the metastatic deposits retain benign ameloblastoma histology.
pathophysiology:
- name: BRAF V600E and MAPK-Pathway Activating Mutation
  description: >-
    Somatic activating mutations in the MAPK pathway, most commonly BRAF V600E
    (valine-to-glutamic-acid substitution at codon 600; pooled prevalence ~70% across
    833 cases), lock BRAF kinase in a constitutively active state. Additional MAPK
    drivers include FGFR2 (upstream RTK), KRAS, NRAS, and HRAS. These mutations are
    most frequent in mandibular tumors.
  cell_types:
  - preferred_term: odontogenic epithelial cell
    term:
      id: CL:0000059
      label: ameloblast
  gene_products:
  - preferred_term: BRAF V600E mutant kinase
    term:
      id: NCIT:C17476
      label: Serine/Threonine-Protein Kinase B-Raf
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  evidence:
  - reference: PMID:36428683
    reference_title: "BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meta-analysis prevalence of BRAF V600E in ameloblastoma was 70.49%, and a significant meta-analysis association was reported for those younger than 54 years old and in the mandible."
    explanation: >-
      Meta-analysis of 833 cases establishes BRAF V600E as the dominant somatic
      driver and its enrichment in mandibular tumors.
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we report the establishment of 6 new AB cell lines-generated by \"conditional reprogramming\"-and their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."
    explanation: >-
      Genomic characterization of patient-derived ameloblastoma cell lines confirms
      the spectrum of MAPK-pathway driver mutations (FGFR2, KRAS, NRAS, BRAF).
  downstream:
  - target: Constitutive Odontogenic Epithelial Proliferation
    description: >-
      Constitutively active BRAF continuously phosphorylates MEK and ERK, driving
      growth-promoting transcription independent of upstream growth-factor signaling.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Hedgehog Pathway SMO Activating Mutation
  description: >-
    Activating mutations in SMO (Smoothened), most commonly SMO-L412F and less commonly
    SMO-W535L, drive ligand-independent Hedgehog signaling and GLI-driven transcription.
    SMO mutations are more typical of maxillary ameloblastomas and represent an
    alternative oncogenic route to odontogenic epithelial proliferation.
  cell_types:
  - preferred_term: odontogenic epithelial cell
    term:
      id: CL:0000059
      label: ameloblast
  biological_processes:
  - preferred_term: smoothened signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007224
      label: smoothened signaling pathway
  evidence:
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "AB cells with activating SMO-L412F mutation (Hedgehog pathway) are insensitive to vismodegib; however, a distinct small-molecule SMO inhibitor, BMS-833923, significantly reduces both downstream Hedgehog signaling and tumor cell viability."
    explanation: >-
      Functional data confirm constitutive Hedgehog signaling driven by the SMO-L412F
      mutation in ameloblastoma cells.
  downstream:
  - target: Constitutive Odontogenic Epithelial Proliferation
    description: >-
      Constitutive SMO activation drives GLI-dependent transcription of proliferation
      and differentiation genes in odontogenic epithelium.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Constitutive Odontogenic Epithelial Proliferation
  description: >-
    Convergent MAPK and Hedgehog signaling drive uncontrolled proliferation of
    odontogenic epithelial cells with evasion of apoptosis, producing the islands,
    cords, and sheets of tumor epithelium characteristic of ameloblastoma.
  cell_types:
  - preferred_term: odontogenic epithelial cell
    term:
      id: CL:0000059
      label: ameloblast
  biological_processes:
  - preferred_term: epithelial cell proliferation
    modifier: INCREASED
    term:
      id: GO:0050679
      label: positive regulation of epithelial cell proliferation
  - preferred_term: apoptosis evasion
    modifier: INCREASED
    term:
      id: GO:0043066
      label: negative regulation of apoptotic process
  evidence:
  - reference: PMID:38812739
    reference_title: "Identification of Molecular Mechanisms of Ameloblastoma and Drug Repositioning by Integration of Bioinformatics Analysis and Molecular Docking Simulation."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Ameloblastoma (AM) is a benign tumor locally originated from odontogenic epithelium that is commonly found in the jaw. This tumor makes aggressive invasions and has a high recurrence rate."
    explanation: >-
      Transcriptomic and network analysis characterizes ameloblastoma as an
      odontogenic-epithelium-derived tumor with aggressive, invasive proliferation.
  downstream:
  - target: Local Bone Invasion and Destruction
    description: >-
      Expanding tumor epithelium infiltrates medullary spaces and resorbs cortical
      bone of the jaw.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Local Bone Invasion and Destruction
  description: >-
    The locally invasive tumor infiltrates through the medullary spaces of the jawbone
    and resorbs cortical bone, destroying normal bone architecture and creating the
    characteristic unilocular or multilocular radiolucencies. Infiltration beyond
    radiographic margins underlies the high recurrence rate.
  cell_types:
  - preferred_term: osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  biological_processes:
  - preferred_term: bone resorption
    modifier: INCREASED
    term:
      id: GO:0045453
      label: bone resorption
  evidence:
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although relatively uncommon and rarely metastatic, AB tumors are locally invasive and destructive to the jawbone and surrounding structures."
    explanation: >-
      Describes the locally invasive, bone-destructive behavior that produces the
      clinical phenotypes of ameloblastoma.
  downstream:
  - target: Jaw Swelling
    description: >-
      Progressive tumor growth and cortical expansion produce painless jaw swelling.
    causal_link_type: DIRECT
  - target: Tooth Malposition
    description: >-
      Tumor expansion displaces teeth within the affected jaw region.
    causal_link_type: DIRECT
  - target: Facial Asymmetry
    description: >-
      Unilateral jaw expansion produces visible facial deformity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Paresthesia
    description: >-
      Tumor involvement of the inferior alveolar nerve produces altered sensation.
    causal_link_type: DIRECT
phenotypes:
- name: Jaw Swelling
  category: Phenotypic
  description: >-
    Painless, slowly progressive swelling of the mandible or maxilla with expansion
    of buccal and lingual cortical plates; present in nearly all cases at diagnosis.
  phenotype_term:
    preferred_term: Jaw swelling
    term:
      id: HP:0030793
      label: Jaw swelling
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:38927880
    reference_title: "Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Ameloblastoma, a benign yet aggressive odontogenic tumor known for its recurrence and the severe morbidity from radical surgeries, may benefit from advancements in targeted therapy."
    explanation: >-
      Indirect support: the cited quote establishes ameloblastoma as a benign but
      locally aggressive jaw tumor. Jaw swelling is the well-recognized hallmark
      presentation clinically, but this abstract does not name the swelling
      phenotype directly, so the association is marked PARTIAL.
- name: Odontogenic Neoplasm
  category: Phenotypic
  description: >-
    Ameloblastoma is the most common odontogenic neoplasm of the jaws, accounting for
    a large proportion of odontogenic tumors.
  phenotype_term:
    preferred_term: Odontogenic neoplasm
    term:
      id: HP:0100612
      label: Odontogenic neoplasm
  evidence:
  - reference: PMID:38021761
    reference_title: "The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ameloblastoma is one of the most prevalent but enigmatic benign odontogenic tumors of the jaw, accounting for approximately 10% of all maxillary and mandibular tumors."
    explanation: >-
      Confirms ameloblastoma as a benign odontogenic tumor of the jaw.
- name: Facial Asymmetry
  category: Phenotypic
  description: >-
    Noticeable facial deformity resulting from unilateral jaw expansion in established
    disease.
  phenotype_term:
    preferred_term: Facial asymmetry
    term:
      id: HP:0000324
      label: Facial asymmetry
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:38021761
    reference_title: "The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "This neoplasia is distinguished by exhibiting several clinical and histological variants along with several mutations that affect its behavior."
    explanation: >-
      Indirect support: facial asymmetry arises from progressive unilateral jaw
      expansion in advanced ameloblastoma. The abstract speaks to clinical
      variability but does not name facial asymmetry directly, so the link is
      marked PARTIAL.
- name: Tooth Malposition
  category: Phenotypic
  description: >-
    Displacement and mobility of teeth within the affected jaw region, which can lead
    to tooth loss and impaired mastication.
  phenotype_term:
    preferred_term: Tooth malposition
    term:
      id: HP:0000692
      label: Tooth malposition
  evidence:
  - reference: PMID:30614154
    reference_title: "Global incidence and profile of ameloblastoma: A systematic review and meta-analysis."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "A slight male preference (53%) was found, and the mandible appeared to be the preferred site."
    explanation: >-
      Indirect support: mandibular tumors (the preferred site established by this
      meta-analysis) characteristically displace teeth as they expand, but the
      abstract does not name tooth displacement directly, so the link is PARTIAL.
- name: Premature Loss of Teeth
  category: Phenotypic
  description: >-
    Progressive tumor expansion and bone destruction can lead to loss of teeth in the
    involved region.
  phenotype_term:
    preferred_term: Premature loss of teeth
    term:
      id: HP:0006480
      label: Premature loss of teeth
  evidence:
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "AB tumors are locally invasive and destructive to the jawbone and surrounding structures."
    explanation: >-
      Indirect support: local destruction of the jawbone and surrounding
      structures plausibly underlies tooth loss, but the abstract does not name
      tooth loss directly, so the link is marked PARTIAL.
- name: Paresthesia
  category: Phenotypic
  description: >-
    Numbness or altered sensation, particularly when the inferior alveolar nerve is
    involved; occurs more often in advanced disease.
  phenotype_term:
    preferred_term: Paresthesia
    term:
      id: HP:0003401
      label: Paresthesia
  evidence:
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "AB tumors are locally invasive and destructive to the jawbone and surrounding structures."
    explanation: >-
      Invasion of surrounding structures, including the inferior alveolar nerve canal,
      produces paresthesia; this snippet supports the local-invasion basis of the
      phenotype rather than the symptom frequency.
histopathology:
- name: Follicular Pattern
  finding_term:
    preferred_term: Follicular ameloblastoma
    term:
      id: NCIT:C27397
      label: Follicular Ameloblastoma
  frequency: FREQUENT
  description: >-
    Islands of odontogenic epithelium with peripheral palisading and reverse
    polarization surrounding a central stellate reticulum-like tissue; the most common
    histologic pattern globally.
  evidence:
  - reference: PMID:30614154
    reference_title: "Global incidence and profile of ameloblastoma: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The histopathologic patterns were mostly follicular and plexiform."
    explanation: >-
      Systematic review of 6,446 patients identifies follicular as a predominant
      histopathologic pattern.
- name: Plexiform Pattern
  finding_term:
    preferred_term: Plexiform ameloblastoma
    term:
      id: NCIT:C39753
      label: Plexiform Ameloblastoma
  frequency: FREQUENT
  description: >-
    Anastomosing cords and sheets of odontogenic epithelium; the second most common
    histologic pattern.
  evidence:
  - reference: PMID:30614154
    reference_title: "Global incidence and profile of ameloblastoma: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The histopathologic patterns were mostly follicular and plexiform."
    explanation: >-
      Systematic review identifies plexiform as a predominant histopathologic pattern.
genetic:
- name: BRAF
  gene_term:
    preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  notes: >-
    Somatic BRAF V600E (p.Val600Glu) missense mutation is the most common driver,
    with a pooled prevalence of ~70% across 833 cases. It causes constitutive,
    ligand-independent MAPK signaling and is enriched in mandibular tumors and younger
    patients. BRAF V600E status guides eligibility for BRAF-inhibitor therapy.
  evidence:
  - reference: PMID:36428683
    reference_title: "BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The discovery that ameloblastoma has a high mutation incidence of BRAF V600E may enable a better investigation of pathophysiology."
    explanation: >-
      Establishes BRAF V600E as the high-frequency somatic driver of ameloblastoma.
- name: SMO
  gene_term:
    preferred_term: SMO
    term:
      id: hgnc:11119
      label: SMO
  notes: >-
    Activating SMO mutations (most commonly SMO-L412F, less commonly SMO-W535L) drive
    constitutive Hedgehog signaling and are more typical of maxillary ameloblastomas.
  evidence:
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "AB cells with activating SMO-L412F mutation (Hedgehog pathway) are insensitive to vismodegib; however, a distinct small-molecule SMO inhibitor, BMS-833923, significantly reduces both downstream Hedgehog signaling and tumor cell viability."
    explanation: >-
      Confirms the activating SMO-L412F mutation and its Hedgehog-pathway consequences
      in ameloblastoma cells.
- name: FGFR2
  gene_term:
    preferred_term: FGFR2
    term:
      id: hgnc:3689
      label: FGFR2
  notes: >-
    Activating FGFR2 mutations act as an upstream receptor-tyrosine-kinase driver of
    MAPK signaling in a subset of ameloblastomas.
  evidence:
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."
    explanation: >-
      Genomic characterization of ameloblastoma cell lines identifies FGFR2 among
      the driver mutations.
- name: KRAS
  gene_term:
    preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  notes: >-
    Activating KRAS mutations (e.g., codon 12) drive constitutive RAS-MAPK signaling;
    KRAS/NRAS-mutant cells are exquisitely sensitive to MEK inhibition.
  evidence:
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
    explanation: >-
      Confirms KRAS as a MAPK-pathway driver and establishes MEK-inhibitor sensitivity.
- name: NRAS
  gene_term:
    preferred_term: NRAS
    term:
      id: hgnc:7989
      label: NRAS
  notes: >-
    Activating NRAS mutations drive constitutive RAS-MAPK signaling; NRAS-mutant cells
    respond to MEK inhibition.
  evidence:
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
    explanation: >-
      Confirms NRAS as a MAPK-pathway driver in ameloblastoma.
- name: HRAS
  gene_term:
    preferred_term: HRAS
    term:
      id: hgnc:5173
      label: HRAS
  notes: >-
    Activating HRAS mutations are a less common RAS-family MAPK-pathway driver in
    ameloblastoma.
  evidence:
  - reference: PMID:35689405
    reference_title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "Recent genomic studies of AB have uncovered oncogenic driver mutations, including in the mitogen-activated protein kinase (MAPK) and Hedgehog signaling pathways."
    explanation: >-
      HRAS is part of the RAS family of MAPK-pathway drivers uncovered in genomic
      studies of ameloblastoma.
treatments:
- name: Radical Surgical Resection
  description: >-
    Segmental mandibulectomy or maxillectomy with 1.5-2 cm safety margins (en bloc
    resection), typically with immediate reconstruction (e.g., vascularized fibula
    free flap). Radical resection achieves the lowest recurrence rate (~11%) but
    carries significant functional and aesthetic morbidity.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:38927880
    reference_title: "Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ameloblastoma, a benign yet aggressive odontogenic tumor known for its recurrence and the severe morbidity from radical surgeries, may benefit from advancements in targeted therapy."
    explanation: >-
      Establishes radical surgery as the standard treatment and the source of severe
      morbidity that motivates targeted alternatives.
- name: Conservative Surgical Resection
  description: >-
    Enucleation, curettage, or marginal resection for smaller lesions, unicystic
    luminal/intraluminal types, and younger patients. Offers better functional and
    aesthetic outcomes but carries a substantially higher recurrence rate (up to 65%).
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:38021761
    reference_title: "The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The ameloblastoma treatment plan is determined by the tumor's size, anatomical location, histologic variant, and anatomical involvement."
    explanation: >-
      Supports the size/location/variant-driven choice between conservative and
      radical surgical approaches.
- name: BRAF/MEK Inhibitor Targeted Therapy
  description: >-
    Pharmacotherapy targeting the MAPK pathway in BRAF V600E-mutant ameloblastoma,
    typically dabrafenib (BRAF inhibitor) combined with trametinib (MEK inhibitor),
    or vemurafenib. Used as neoadjuvant therapy to shrink tumors before conservative
    surgery, and in recurrent, metastatic, or unresectable disease. A systematic
    review of 23 patients reported that nearly all responded, with 4 complete
    radiologic remissions.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dabrafenib
      term:
        id: CHEBI:75045
        label: dabrafenib
    - preferred_term: trametinib
      term:
        id: CHEBI:75998
        label: trametinib
    - preferred_term: vemurafenib
      term:
        id: CHEBI:63637
        label: vemurafenib
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: BRAF V600E and MAPK-Pathway Activating Mutation
  evidence:
  - reference: PMID:38927880
    reference_title: "Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "covering 23 patients treated with MAPK inhibitor therapies. The results were promising as nearly all patients showed a positive treatment response, with four achieving complete radiological remission and others showing substantial reductions in primary, recurrent, and metastatic ameloblastoma sizes."
    explanation: >-
      Systematic review evidence that anti-MAPK targeted therapy produces responses,
      including complete remissions, in ameloblastoma.
  - reference: PMID:37115331
    reference_title: "BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These included seven case reports with nine patients who underwent monotherapy with Dabrafenib or Vemurafenib or combination therapy with Dabrafenib and Trametinib."
    explanation: >-
      Documents the BRAF/MEK inhibitor regimens (dabrafenib, vemurafenib, dabrafenib
      plus trametinib) used in BRAF V600E-mutant ameloblastoma.
references:
- reference: PMID:36428683
  title: "BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis."
- reference: PMID:35689405
  title: "New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies."
- reference: PMID:38927880
  title: "Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review."
- reference: PMID:30614154
  title: "Global incidence and profile of ameloblastoma: A systematic review and meta-analysis."
- reference: PMID:38021761
  title: "The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review."
- reference: PMID:38812739
  title: "Identification of Molecular Mechanisms of Ameloblastoma and Drug Repositioning by Integration of Bioinformatics Analysis and Molecular Docking Simulation."
- reference: PMID:37115331
  title: "BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature."

📚

References & Deep Research